Oral (Gavage) Combined Developmental and Perinatal/Postnatal Reproduction Toxicity Study of Ammonium Salt of Perfluorinated Hexanoic Acid in Mice.
The reproductive toxicity potential of Ammonium Salt of Perfluorinated Hexanoic Acid (PFHxA Ammonium Salt) in pregnant Crl: CD1(ICR) mice was investigated. Twenty females/group were administered the test substance or vehicle once daily from gestation day 6 through 18. Phase 1 doses: 0, 100, 350, and 500 mg/kg/d; phase 2: 0, 7, 35, and 175 mg/kg/d. Parameters evaluated include mortality, viability, body weights, clinical signs, abortions, premature deliveries, pregnancy and fertility, litter observations, maternal behavior, and sexual maturity in the F1 generation. The level of PFHxA Ammonium Salt was measured in the liver of F0 and F1 mice. At doses of 350 and 500 mg/kg/d maternal mortalities, excess salivation and changes in body weight gains occurred. Pup body weights were reduced on postpartum day (PPD) 0 in all the dosage groups, but persisted only in the 350 and 500 mg/kg/d groups. Additional effects at 300 and 500 mg/kg/d included stillbirths, reductions in viability indices, and delays in physical development. Levels of PFHxA Ammonium Salt in the livers of the 100 mg/kg/d dams were all below the lower limit of quantization (0.02 µg/mL); in the 350 mg/kg/d group, 3 of the 8 samples had quantifiable analytical results. In phase 2 no PFHxA Ammonium Salt was found in the liver. Adverse effects occurred only in the 175 mg/kg/d group and consisted of increased stillborn pups, pups dying on PPD 1, and reduced pup weights on PPD 1. Based on these data, the maternal and reproductive no observable adverse effect level of PFHxA Ammonium Salt is 100 mg/kg/d.
Daikin Industries Ltd, Settsu, Osaka, Japan.
Hiroyuki
H
Iwai
Charles River Laboratories, Preclinical Services, Horsham, PA, USA alan.hoberman@crl.com.
Alan M
AM
Hoberman
D000284:Administration, Oral; D000643:Ammonium Chloride / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D002208:Caproates / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004785:Environmental Pollutants / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D005466:Fluorocarbons / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity*; D007247:Infertility, Female / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D007248:Infertility, Male / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D007774:Lactation; D008297:Male; D018811:Maternal Exposure / Q000009:adverse effects*; D051379:Mice; D019055:No-Observed-Adverse-Effect Level; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D011297:Prenatal Exposure Delayed Effects; D012741:Sexual Maturation / Q000187:drug effects; D014018:Tissue Distribution; D066007:Toxicokinetics; D015430:Weight Gain / Q000187:drug effects
D002208:Caproates; D004785:Environmental Pollutants; D005466:Fluorocarbons; D000643:Ammonium Chloride; C479228:perfluorohexanoic acid
PFHxA Ammonium Salt; mouse reproductive study